Gapping up
In reaction to strong earnings/guidance: NSPR +16%, WTW +15.7%, HDP +13.5%, OSUR +13.3%, RAIL +11.6%, FUEL +9.9%, ZU +9.3%, POWR +7.6%, HLF +7.5%, OME +7.5%, SSNI +7%, AAOI +6.2%, XPO +4.7%, ACAS +4.2%, LGCY +3.3%, ALB +3.3%, TSO +2.9%, CSLT +2.7%, NLY +2.7%, (Annaly Capital Mgmt and Chimera Investment Corporation (CIM) announce the internalization of Chimera mgmt; Chimera will purchase Annaly's stake in the company for $126.4 mln ), TK +2%, SD +1.6%, WTI +1.6%, SEMI +1.5%, PRU +1.4%, DOOR +1.3%, CBPO +1.3%, SWM +1.2%, ABX +1.2%, DXCM +1%, SBY +1%, GBDC +1%, GORO +1%, CNAT +0.9%, UHAL +0.8%, SUN +0.8%, CXW +0.7%, EVTC +0.6%, DCO +0.6%, PACB+0.5%, GNRC +0.5%
M&A news: CO +26.2% (receives a non-binding acquisition proposal letter from Nanjing Xinjiekou Department Store to acquire all of CO's China business, purchase price offered is not lower than RMB 6 bln), MDLZ +5.6% (Pershing Square discloses 7.5% stake in Mondelez), CF +4.9% (to combine with OCI N.V.'s OCI's (OCINY) European, North American and Global Distribution businesses in a transaction valued at ~$8 bln)
Select metals/mining stocks trading higher: AU +1.8%, AUY +1.7%, ABX +1.7%
Other news: NSPR +20% (entered into a partnership with Penumbra to distribute its carotid CGuard EPS through a direct commercialization team; co also reported earnings), GENE +19.6% (announces the issuance of a US Patent covering three of the core genetic markers referred to as single-nucleotide polymorphisms in the Company's BREVAGenplus risk assessment test),OREX +11.3% (Orexigen Therapeutics and Takeda (TKPYY) amend and restate their collaboration agreement to resolve all outstanding disputes between the companies and align the partnership for the continued long-term success of CONTRAVE), NBG +4.2% (cont vol in Greece markets), NLY +2.6% (Board authorized $1 bln common stock share repurchase program; co and Chimera Investment Corporation (CIM) announce the internalization of Chimera's management; Chimera to purchase co's 4.4% stake in Chimera for $126.4 mln; co also reported earnings), GSK +2.6% (still checking), RGLD +2% (announced an agreement to purchase Barrick Gold's (ABX) 60% interest in its Pueblo Viejo mine, for $610 mln), RRD +1.9% (favorable commentary on Wednesday's Mad Money), NFLX +1.6% (favorable commentary on Wednesday's Mad Money), PYPL +1% (cont vol post IPO)
Analyst comments: S +4.1% (upgraded to Outperform at FBR Capital ), SSYS +3.3% (upgraded to Buy from Neutral at Citigroup)
In reaction to strong earnings/guidance: NSPR +16%, WTW +15.7%, HDP +13.5%, OSUR +13.3%, RAIL +11.6%, FUEL +9.9%, ZU +9.3%, POWR +7.6%, HLF +7.5%, OME +7.5%, SSNI +7%, AAOI +6.2%, XPO +4.7%, ACAS +4.2%, LGCY +3.3%, ALB +3.3%, TSO +2.9%, CSLT +2.7%, NLY +2.7%, (Annaly Capital Mgmt and Chimera Investment Corporation (CIM) announce the internalization of Chimera mgmt; Chimera will purchase Annaly's stake in the company for $126.4 mln ), TK +2%, SD +1.6%, WTI +1.6%, SEMI +1.5%, PRU +1.4%, DOOR +1.3%, CBPO +1.3%, SWM +1.2%, ABX +1.2%, DXCM +1%, SBY +1%, GBDC +1%, GORO +1%, CNAT +0.9%, UHAL +0.8%, SUN +0.8%, CXW +0.7%, EVTC +0.6%, DCO +0.6%, PACB+0.5%, GNRC +0.5%
M&A news: CO +26.2% (receives a non-binding acquisition proposal letter from Nanjing Xinjiekou Department Store to acquire all of CO's China business, purchase price offered is not lower than RMB 6 bln), MDLZ +5.6% (Pershing Square discloses 7.5% stake in Mondelez), CF +4.9% (to combine with OCI N.V.'s OCI's (OCINY) European, North American and Global Distribution businesses in a transaction valued at ~$8 bln)
Select metals/mining stocks trading higher: AU +1.8%, AUY +1.7%, ABX +1.7%
Other news: NSPR +20% (entered into a partnership with Penumbra to distribute its carotid CGuard EPS through a direct commercialization team; co also reported earnings), GENE +19.6% (announces the issuance of a US Patent covering three of the core genetic markers referred to as single-nucleotide polymorphisms in the Company's BREVAGenplus risk assessment test),OREX +11.3% (Orexigen Therapeutics and Takeda (TKPYY) amend and restate their collaboration agreement to resolve all outstanding disputes between the companies and align the partnership for the continued long-term success of CONTRAVE), NBG +4.2% (cont vol in Greece markets), NLY +2.6% (Board authorized $1 bln common stock share repurchase program; co and Chimera Investment Corporation (CIM) announce the internalization of Chimera's management; Chimera to purchase co's 4.4% stake in Chimera for $126.4 mln; co also reported earnings), GSK +2.6% (still checking), RGLD +2% (announced an agreement to purchase Barrick Gold's (ABX) 60% interest in its Pueblo Viejo mine, for $610 mln), RRD +1.9% (favorable commentary on Wednesday's Mad Money), NFLX +1.6% (favorable commentary on Wednesday's Mad Money), PYPL +1% (cont vol post IPO)
Analyst comments: S +4.1% (upgraded to Outperform at FBR Capital ), SSYS +3.3% (upgraded to Buy from Neutral at Citigroup)